UPDATED: FDA hurries up a quick approval for the world's first TCR — after a 14-year R&D trek
Over the 14 years since Immunocore was spun out of MediGene in a quest to develop a gamechanging cancer med, the biotech has raised record sums and undergone a major shakeup on a long roller coaster ride of valuations for investors. But they survived and thrived and today they’re popping the champagne corks to celebrate an FDA approval of their first TCR drug.
Immunocore flagged the FDA’s green light for tebentafusp Wednesday morning by highlighting a series of firsts.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.